Adelaide, Australia – Agilex Biolabs, Australia’s most advanced FDA-inspected specialist bioanalytical laboratory for clinical trials, has brought forward implementation of the Agilex Client Portal in response to the continued global COVID-19 outbreak and increased client demand for the Australian biolab.

The Agilex Client Portal is the first of its type globally for a major bioanalytics company.

The Client Portal is particularly valuable for international clients working across different time zones requiring instant access to real-time study data from the labs.

The highly secure Portal is currently in final live testing with a number of US clients and will be rolled out in January and offered to all clients.

Agilex Biolabs CEO Jason Valentine said:

“This is just another way we are adapting to the international COVID-19 environment to support our clients.

Australian clinical trials have remained open for business and Agilex Biolabs is a designated essential service so clients can be assured of study continuity.

Australia has led the world in keeping COVID-19 numbers down to almost zero in many regions by acting swiftly to minor outbreaks. A 6-day “circuit breaker” is currently in place in Adelaide due to 30 cases, and Melbourne has just come out of a longer lockdown.

We have extensive COVID protocols in place to respond immediately to circuit breakers, ensuring safety for our team and business as usual for our clients.”

Agilex Biolabs, which has a 20-year track-record, is known internationally for its continued investment in the latest technology, and for attracting some of the leading scientists from Australia and around the world.

Agilex Biolabs, the only FDA-inspected lab of its type in the region, also features a rebate of up to 43.5% on clinical trial bioanalytical services spend as part of the Australian Government clinical trial attraction program.

Agilex Biolabs’ world-class bioanalytical facilities have OECD GLP Recognition with NATA (Australian Government OECD GLP Compliance monitoring authority) and ISO 17025 Accreditation for global recognition.

The company has recently expanded its labs by more than 30% to accommodate biotech demand from APAC and the USA. Watch the New Labs Walkthrough Video Here https://www.agilexbiolabs.com/new-labs-video

Agilex Biolabs specialises in bioanalysis of small molecules and biologics for PK, immunogenicity, biomarkers and immunological pharmacodynamics assessments utilising LC-MS/MS, immunoassay (Mesoscale, Gyrolab, Luminex) and flow cytometry (BD FACSymphony A3, 20 colour cell analyser).

Agilex also offers pharmacodynamics servicesthat include immunobiology services using the latest state-of-the-art technology to support immunology, cell biology and mode of action assays, including:

·           Immunophenotyping

  •       Receptor occupancy

·           Cytokine release assays (whole blood or PBMC stimulation assays) and

           cytokine/biomarker profiling

  •       PBMC assays and cellular mechanism of action assays (eg: ADCC)

Agilex Biolabs has more than 95 staff which includes 75 dedicated laboratory staff, and annually support more than 80 clinical trials. This year they will analyse more than 60,000 samples for pharma/biotechs companies from US, Europe and APAC.

Please Book a Briefing with us before you start your next clinical trial.

About Agilex Biolabs https://www.agilexbiolabs.com/

Agilex Biolabs, Australia’s leading bioanalytical laboratory, has more than 20 years’ experience in performing regulated bioanalysis, including quality method development, method validation and sample analysis services. We have successfully supported hundreds of preclinical and clinical trials around the world where customers choose Australia for the streamlined regulatory process and access to the world’s most attractive R&D rebate of more than 40% on clinical trial work conducted in Australia.

We offer services for both small molecules and biologics for PK, immunogenicity (PD) and biomarker bioanalysis utilising the two platforms of LC-MS/MS and Immunoassay.